The honest answer is yes — and no. It depends on who you ask and what you value. The current generation of ALS drugs extends life by roughly two to six months on average, a window that strikes some observers as negligible and others as sacred. For a person watching their body shut down over the course of three to five years, those months might mean seeing a grandchild born, finishing a letter, or simply being present for one more holiday. For a healthcare system already buckling under the weight of astronomical drug prices, paying upward of $171,000 a year for a few extra months raises hard questions about resource allocation and what we actually owe people facing terminal illness. ALS — amyotrophic lateral sclerosis, often called Lou Gehrig’s disease — strikes roughly 5,000 new people in the United States every year.
The median survival from symptom onset is about 30 months. That is not a typo. From the moment symptoms appear, most patients have less than three years. Against that backdrop, even a modest extension of life takes on weight that raw numbers cannot capture. But the story is more complicated than a simple months-gained calculation, and the recent collapse of one high-profile ALS drug should give everyone pause. This article examines what the current ALS drugs actually deliver, what they cost, the cautionary tale of Relyvrio’s rise and fall, the emerging treatments that could change the calculus entirely, and the deeply personal question of whether a few additional months of life can ever be reduced to a cost-benefit analysis.
Table of Contents
- How Much Life Do Current ALS Drugs Actually Add?
- The Relyvrio Cautionary Tale and Why Approval Does Not Mean Proof
- What Do ALS Drugs Actually Cost — and Who Pays?
- How Patients and Families Weigh the Value of Extra Months
- Emerging Treatments That Could Change the Equation
- Why Age at Diagnosis Changes Everything About Treatment Value
- Where ALS Treatment Goes From Here
- Conclusion
How Much Life Do Current ALS Drugs Actually Add?
Three FDA-approved drugs currently target ALS, and none of them is a cure. Riluzole, approved back in 1995, remains the standard of care. It extends survival by approximately two to three months and increases the chance of living an additional year by about 9 percent. Those numbers are modest by any measure, but riluzole is relatively inexpensive and widely covered by insurance, which keeps it accessible. For most patients, it is a default choice — not because it is transformative, but because the alternative is nothing. Edaravone, marketed as Radicava, paints a slightly more optimistic picture. Retrospective data showed patients on edaravone survived a median of 29.5 months compared to 23.5 months without it — a roughly six-month extension.
But that benefit comes at a staggering annual cost of approximately $171,000. The Institute for Clinical and Economic Review, an independent watchdog, assessed edaravone’s value-based price benchmark at just $1,400 to $3,200 per year. The gap between what the drug costs and what it is arguably worth is enormous. Then there is tofersen, sold as Qalsody, which earned FDA accelerated approval in April 2023. Tofersen is notable because it is the first ALS drug to target a specific genetic cause — mutations in the SOD1 gene. The catch is that SOD1-ALS accounts for only about 2 percent of all ALS cases. In trials, roughly 25 percent of participants showed stabilization or improvement, which is genuinely meaningful for those patients. But at approximately $200,000 for the first year of treatment and $185,000 annually thereafter, it serves a sliver of the ALS population at a price most health systems strain to absorb.
The Relyvrio Cautionary Tale and Why Approval Does Not Mean Proof
The story of Relyvrio is the most important recent chapter in ALS drug development, and it should be required reading for anyone evaluating new treatments. Approved by the FDA in September 2022, Relyvrio was based on a small Phase 2 trial that suggested a survival benefit of roughly five to six months. The FDA’s own advisory committee initially voted 6 to 4 against approval. The agency overrode that skepticism, granting the drug market access amid intense pressure from patient advocacy groups desperate for any new option. The gamble did not pay off. In March 2024, Relyvrio failed its Phase 3 confirmatory trial — the larger, more rigorous study meant to validate those early results.
The drug did not outperform a placebo. By April 2024, manufacturer Amylyx Pharmaceuticals voluntarily withdrew it from the market and cut 70 percent of its workforce. The FDA formally withdrew approval in August 2025. Patients who had placed their hopes in Relyvrio were left with nothing, and the episode raised uncomfortable questions about whether accelerated approval pathways create false hope when the underlying evidence is thin. However, the Relyvrio story is not simply a failure of the FDA. It also illustrates a genuine dilemma: when a disease kills within years and there are almost no options, how much evidence is enough? If a small trial suggests benefit, do you wait years for confirmation while patients die? There is no clean answer, but the lesson is clear — approval is not the same as proof, and patients and caregivers should understand that accelerated approval means the drug is still essentially on probation.
What Do ALS Drugs Actually Cost — and Who Pays?
The economics of ALS treatment are brutal. A patient taking edaravone faces roughly $171,000 per year in drug costs alone, not counting the infusion appointments, travel, caregiver time, and supplementary care that ALS demands. Tofersen runs about $14,230 per dose, totaling around $200,000 in the first year. Even riluzole, the cheapest option, adds costs on top of the already devastating financial burden of living with a progressive neurodegenerative disease. To put these numbers in context, consider that ICER rated both Relyvrio and oral edaravone as “low” long-term value for money at their current pricing.
This is not a fringe opinion. Among 92 cancer drugs approved between 2000 and 2016, the average survival benefit was less than three months — comparable to what ALS drugs deliver. The pharmaceutical industry has broadly normalized charging six-figure annual prices for drugs that extend life by weeks or months, and ALS therapies follow that same pattern. For patients, insurance coverage often determines access. Medicare and private insurers generally cover riluzole without much friction. Edaravone and tofersen coverage can be far more contentious, requiring prior authorizations, appeals, and sometimes outright denials. Patients diagnosed after age 65 — who already face shorter median survival of about 26 months — may find themselves fighting insurance bureaucracies during what little time they have left.
How Patients and Families Weigh the Value of Extra Months
The clinical framing of ALS drugs — “extends life by two to three months” — can sound dismissive in a way that misrepresents the lived experience. For a 42-year-old parent with two young children, three months is summer vacation. It is a birthday party. It is time to record video messages or settle financial affairs. Patient advocates argue, with considerable moral force, that reducing these months to a line item on a cost-effectiveness spreadsheet misses the point entirely. The ALS Association has pushed this perspective forcefully, urging the FDA to act with urgency on new therapies and stating plainly that “people living with ALS have no time to waste.” That urgency is justified by the math: if median survival is 30 months and a drug takes two years to reach market, many patients diagnosed today will never benefit from it.
The pressure to approve drugs quickly is not irrational — it reflects the reality of a disease that kills faster than the regulatory process moves. But there is a counterpoint that deserves honest acknowledgment. Not every month gained is a good month. ALS progressively strips away the ability to move, speak, eat, and eventually breathe. A drug that extends life by three months but does not slow functional decline may be adding time in a condition the patient would not have chosen. The quality of those months matters as much as their quantity, and this is a conversation that too often gets lost in the advocacy for faster approvals.
Emerging Treatments That Could Change the Equation
The pipeline of ALS therapies in 2025 and 2026 looks more promising than it has in years, though “promising” in ALS research has a history of not panning out. Low-dose interleukin-2, or IL-2, added to standard treatment, reduced the risk of death by over 40 percent in certain patient subgroups in data published in May 2025. If those results hold in larger trials, IL-2 would represent a meaningful leap beyond the incremental gains of current therapies. Pridopidine is another candidate generating cautious optimism. Its Phase 3 PREVAiLS trial began recruiting in early 2026, enrolling 500 patients across 60 centers globally. Earlier-stage data showed a 32 percent slowing of disease progression and a 57 percent improvement in survival — numbers that, if confirmed, would dwarf anything currently available.
VTx-002, developed by VectorY, received FDA Fast Track designation in January 2026 and has entered Phase 1/2 trials. Over 16 biotech companies are actively advancing ALS drug candidates, a level of industry investment that was unthinkable a decade ago. The warning here is important: early-stage trial data almost always looks better than what Phase 3 trials ultimately confirm. Relyvrio’s Phase 2 results looked compelling too. Patients and families following the pipeline should maintain hope while understanding that the majority of drug candidates fail in late-stage testing. The statistical history is unforgiving, and emotional investment in an unproven therapy carries its own cost.
Why Age at Diagnosis Changes Everything About Treatment Value
One factor that rarely gets enough attention in the “is it worth it” debate is the patient’s age at diagnosis. ALS diagnosed before age 40 carries a markedly different prognosis — many of these patients survive 10 or more years. For younger patients with slower disease progression, a drug that extends life by a few months represents a tiny fraction of their overall disease course. But for patients diagnosed after 65, whose median survival is roughly 26 months, those same two to three months represent nearly a 10 percent extension of remaining life.
The proportional value of the same drug shifts dramatically depending on who is taking it. This has practical implications for treatment decisions. A younger patient with slow-progressing ALS might reasonably decide that the side effects and costs of edaravone are not justified by a modest survival gain, particularly if their disease trajectory already favors a longer course. An older patient with rapidly progressing symptoms might view those same months as essential. One-size-fits-all recommendations do not serve ALS patients well, and honest conversations with neurologists about individual prognosis should precede any drug decision.
Where ALS Treatment Goes From Here
The next few years will likely determine whether ALS treatment remains in the era of marginal gains or enters a genuinely new phase. The combination of genetic targeting — as demonstrated by tofersen’s approach to SOD1 mutations — and immunomodulatory strategies like low-dose IL-2 suggests that the field is moving toward treatments matched to specific disease mechanisms rather than the blunt, one-drug-fits-all model. If the pridopidine Phase 3 trial delivers results anywhere close to its earlier data, and if gene therapy candidates like VTx-002 prove safe and effective, the conversation about whether ALS drugs are “worth it” could sound very different by 2028. For now, though, the honest answer remains uncomfortable.
The drugs we have extend life modestly, cost enormously, and do not halt the disease. Whether that trade-off is worth it is not a question that regulators, insurers, or even doctors can answer for a patient. It is a deeply individual calculation that depends on what those months mean to the person living them and the people who love them. The best thing the medical system can do is make that choice genuinely available — affordable, informed, and free of false promises.
Conclusion
ALS drugs in their current form offer real but limited benefit. Riluzole adds roughly two to three months for most patients. Edaravone may extend survival by about six months but at extraordinary cost. Tofersen targets only 2 percent of cases. The collapse of Relyvrio is a reminder that early promise does not guarantee real-world effectiveness, and that accelerated approval carries risks alongside its benefits.
These are not miracle drugs, and presenting them as such does patients a disservice. But the trajectory is shifting. With over 16 companies pursuing ALS therapies and several candidates showing far more robust early results than anything that preceded them, there is reason for cautious hope. For patients and families facing ALS today, the practical steps are clear: discuss individual prognosis honestly with a neurologist, understand what current drugs can and cannot do, investigate clinical trial eligibility, and make treatment decisions based on personal values rather than headlines. The question of whether a few months of life is “worth it” has no universal answer — but it deserves to be asked without shame and answered without judgment.
